Compare the Safety and Efficacy of Glimepiride – Metformin with Vildagliptin - Metformin in Type 2 Diabetes Mellitus Patients in a Tertiary Care Hospital
Abstract
BACKGROUND :
The increased prevalence of Type 2 DM leads to increased cardiovascular
morbidity, dyslipidemia, etc. Failure of monotherapy over time suggests the need
for combination therapy to achieve glycemic goals. Combination therapy with
various agents have been implicated in great glycemic control than monotherapy
with single agent.
OBJECTIVES :
To Compare the Safety and Efficacy of Glimepiride – Metformin with Vildagliptin - Metformin in Type 2 Diabetes Mellitus Patients in a Tertiary Care Hospital.
METHODS :
In this prospective, randomised, controlled, open label comparative study,
newly diagnosed Type 2 diabetic patients were assigned to receive either
T.Glimepiride(1 mg) + T.Metformin (500 mg) twice daily (n=35) or
T.Vildagliptin (50mg) + T.Metformin (500 mg) twice daily (n=35) for a period
of 12 weeks to attain good glycemic control. FBS, PPBS at baseline, 6th week
and 12th week, HbA1c at baseline and at 12th week were compared between and
within the groups at baseline and at the end of the study.
RESULTS :
All the 70 patients completed the study. At the end of the study, the mean
fasting blood sugar level at baseline were 179.06mg/dl and 174.03mg/dl
(P=0.43) and at the end 12 weeks were 109.80mg/dl and 104.57mg/dl (P=0.33)
in Group A and Group B respectively. The mean Post prandial blood sugar levels
at baseline were 270.86mg/dl and 277.94mg/dl(P=0.42) and at the end of 12th
week were 159.03mg/dl and 154.45mg/dl (P=0.07) in Group A and Group B
respectively. The…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 70 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.